Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Benha University19 enrolled

Overview

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hyperuricemia Hemodialysis Complication

Interventions

Febuxostat 40 milligramsTabletDRUG

Febuxostat 40 milligramsTablet every other day for 3 months

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age above 18 years * Hemodialysis patient * Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males) Exclusion Criteria: * Patient currently and/or recently received drugs for hyperuricemia within the last three months * Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Outcomes

Primary Outcomes

Change in serum uric acid

Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy

Time frame: at three months of Febuxostat 40 milligrams Tablet therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.